Dataset Information

Development and Clinical Validation of the LymphMonitor Technology to Quantitatively Assess Lymphatic Function.

ABSTRACT: Current diagnostic methods for evaluating the functionality of the lymphatic vascular system usually do not provide quantitative data and suffer from many limitations including high costs, complexity, and the need to perform them in hospital settings. In this work, we present a quantitative, simple outpatient technology named LymphMonitor to quantitatively assess lymphatic function. This method is based on the painless injection of the lymphatic-specific near-infrared fluorescent tracer indocyanine green complexed with human serum albumin, using MicronJet600TM microneedles, and monitoring the disappearance of the fluorescence signal at the injection site over time using a portable detection device named LymphMeter. This technology was investigated in 10 patients with unilateral leg or arm lymphedema. After injection of a tracer solution into each limb, the signal was measured over 3 h and the area under the normalized clearance curve was calculated to quantify the lymphatic function. A statistically significant difference in lymphatic clearance in the healthy versus the lymphedema extremities was found, based on the obtained area under curves of the normalized clearance curves. This study provides the first evidence that the LymphMonitor technology has the potential to diagnose and monitor the lymphatic function in patients.

SUBMITTER: Polomska A

PROVIDER: S-EPMC8534490 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Development and Clinical Validation of the LymphMonitor Technology to Quantitatively Assess Lymphatic Function.

Polomska Anna A Gousopoulos Epameinondas E Fehr Daniel D Bachmann Andreas A Bonmarin Mathias M Detmar Michael M Lindenblatt Nicole N

Diagnostics (Basel, Switzerland) 20211012 10

Current diagnostic methods for evaluating the functionality of the lymphatic vascular system usually do not provide quantitative data and suffer from many limitations including high costs, complexity, and the need to perform them in hospital settings. In this work, we present a quantitative, simple outpatient technology named LymphMonitor to quantitatively assess lymphatic function. This method is based on the painless injection of the lymphatic-specific near-infrared fluorescent tracer indocyan ...[more]

PMID: 34679571

Similar Datasets

Project description:BackgroundThere remains a demand for a practical method of identifying lipid-poor adrenal lesions.PurposeTo explore the predictive value of computed tomography (CT) features combined with demographic characteristics for lipid-poor adrenal adenomas and nonadenomas.Materials and methodsWe retrospectively recruited patients with lipid-poor adrenal lesions between January 2015 and August 2021 from two independent institutions as follows: Institution 1 for the training set and the internal validation set and Institution 2 for the external validation set. Two radiologists reviewed CT images for the three sets. We performed a least absolute shrinkage and selection operator (LASSO) algorithm to select variables; subsequently, multivariate analysis was used to develop a generalized linear model. The probability threshold of the model was set to 0.5 in the external validation set. We calculated the sensitivity, specificity, accuracy, and area under the receiver operating characteristic curve (AUC) for the model and radiologists. The model was validated and tested in the internal validation and external validation sets; moreover, the accuracy between the model and both radiologists were compared using the McNemar test in the external validation set.ResultsIn total, 253 patients (median age, 55 years [interquartile range, 47-64 years]; 135 men) with 121 lipid-poor adrenal adenomas and 132 nonadenomas were included in Institution 1, whereas another 55 patients were included in Institution 2. The multivariable analysis showed that age, male, lesion size, necrosis, unenhanced attenuation, and portal venous phase attenuation were independently associated with adrenal adenomas. The clinical-image model showed AUCs of 0.96 (95% confidence interval [CI]: 0.91, 0.98), 0.93 (95% CI: 0.84, 0.97), and 0.86 (95% CI: 0.74, 0.94) in the training set, internal validation set, and external validation set, respectively. In the external validation set, the model showed a significantly and non-significantly higher accuracy than reader 1 (84% vs. 65%, P = 0.031) and reader 2 (84% vs. 69%, P = 0.057), respectively.ConclusionsOur clinical-image model displayed good utility in differentiating lipid-poor adrenal adenomas. Further, it showed better diagnostic ability than experienced radiologists in the external validation set.

Project description:Importance:Clinical practice guidelines (CPGs) may lack rigor and suitability to the setting in which they are to be applied. Methods to yield clinical practice guideline recommendations that are credible and implementable remain to be determined. Objective:To describe the development of AGREE-REX (Appraisal of Guidelines Research and Evaluation-Recommendations Excellence), a tool designed to evaluate the quality of clinical practice guideline recommendations. Design, Setting, and Participants:A cross-sectional study of 322 international stakeholders representing CPG developers, users, and researchers was conducted between December 2015 and March 2019. Advertisements to participate were distributed through professional organizations as well as through the AGREE Enterprise social media accounts and their registered users. Exposures:Between 2015 and 2017, participants appraised 1 of 161 CPGs using the Draft AGREE-REX tool and completed the AGREE-REX Usability Survey. Main Outcomes and Measures:Usability and measurement properties of the tool were assessed with 7-point scales (1 indicating strong disagreement and 7 indicating strong agreement). Internal consistency of items was assessed with the Cronbach α, and the Spearman-Brown reliability adjustment was used to calculate reliability for 2 to 5 raters. Results:A total of 322 participants (202 female participants [62.7%]; 83 aged 40-49 years [25.8%]) rated the survey items (on a 7-point scale). All 11 items were rated as easy to understand (with a mean [SD] ranging from 5.2 [1.38] for the alignment of values item to 6.3 [0.87] for the evidence item) and easy to apply (with a mean [SD] ranging from 4.8 [1.49] for the alignment of values item to 6.1 [1.07] for the evidence item). Participants provided favorable feedback on the tool's instructions, which were considered clear (mean [SD], 5.8 [1.06]), helpful (mean [SD], 5.9 [1.00]), and complete (mean [SD], 5.8 [1.11]). Participants considered the tool easy to use (mean [SD], 5.4 [1.32]) and thought that it added value to the guideline enterprise (mean [SD], 5.9 [1.13]). Internal consistency of the items was high (Cronbach α = 0.94). Positive correlations were found between the overall AGREE-REX score and the implementability score (r = 0.81) and the clinical credibility score (r = 0.76). Conclusions and Relevance:This cross-sectional study found that the AGREE-REX tool can be useful in evaluating CPG recommendations, differentiating among them, and identifying those that are clinically credible and implementable for practicing health professionals and decision makers who use recommendations to inform clinical policy.

Project description:This article describes the development and validation of a liquid-chromatography coupled with tandem mass spectrometry (LC-MS/MS) assay for the simultaneous quantitation of the BRAF inhibitors dabrafenib and encorafenib, and semi-quantitation of their major metabolites (i.e., carboxy-dabrafenib, desmethyl-dabrafenib, hydroxy-dabrafenib, M42.5A) in human plasma. Analytes were extracted from human plasma by protein precipitation, followed by reversed phase high-performance liquid chromatography. Analyte detection was performed using tandem mass spectrometry with heated electrospray ionization operating in positive ion mode. The assay was validated in accordance with the current U.S. Food and Drug Administration Guidance on Bioanalytical Method Validation. Results showed that measurements were both accurate (94.6-112.0 %) and precise (within-run: 1.9-3.4 %; between-run: 1.7-12.0 %) spanning a concentration range of 5 to 2000 ng/mL for dabrafenib and 10 to 4000 ng/mL for encorafenib. Recoveries for these analytes were consistent with mean values ranging from 85.6 % to 90.9 %. The mean internal standard-normalized matrix factors for each drug ranged between 0.87 and 0.98 and were found to be precise (% RSD <6.4 %). Dabrafenib and encorafenib were stable in the final extract and in human plasma held under various storage conditions. The metabolites also passed the validation criteria for precision and selectivity. Finally, the clinical applicability of the assay was confirmed by (semi-)quantitation of all six analytes in plasma samples from cancer patients receiving standard-of-care treatment with dabrafenib and encorafenib. Reproducibility of the measured analyte concentrations in study samples was confirmed successfully by incurred sample reanalysis. In conclusion, this sensitive LC-MS/MS assay has been validated successfully and is suitable for therapeutic drug monitoring of dabrafenib and encorafenib and clinical pharmacokinetic studies with these BRAF inhibitors.

Project description:BackgroundNatural Language Understanding enables automatic extraction of relevant information from clinical text data, which are acquired every day in hospitals. In 2018, the language model Bidirectional Encoder Representations from Transformers (BERT) was introduced, generating new state-of-the-art results on several downstream tasks. The National NLP Clinical Challenges (n2c2) is an initiative that strives to tackle such downstream tasks on domain-specific clinical data. In this paper, we present the results of our participation in the 2019 n2c2 and related work completed thereafter.ObjectiveThe objective of this study was to optimally leverage BERT for the task of assessing the semantic textual similarity of clinical text data.MethodsWe used BERT as an initial baseline and analyzed the results, which we used as a starting point to develop 3 different approaches where we (1) added additional, handcrafted sentence similarity features to the classifier token of BERT and combined the results with more features in multiple regression estimators, (2) incorporated a built-in ensembling method, M-Heads, into BERT by duplicating the regression head and applying an adapted training strategy to facilitate the focus of the heads on different input patterns of the medical sentences, and (3) developed a graph-based similarity approach for medications, which allows extrapolating similarities across known entities from the training set. The approaches were evaluated with the Pearson correlation coefficient between the predicted scores and ground truth of the official training and test dataset.ResultsWe improved the performance of BERT on the test dataset from a Pearson correlation coefficient of 0.859 to 0.883 using a combination of the M-Heads method and the graph-based similarity approach. We also show differences between the test and training dataset and how the two datasets influenced the results.ConclusionsWe found that using a graph-based similarity approach has the potential to extrapolate domain specific knowledge to unseen sentences. We observed that it is easily possible to obtain deceptive results from the test dataset, especially when the distribution of the data samples is different between training and test datasets.

Dataset Information

Development and Clinical Validation of the LymphMonitor Technology to Quantitatively Assess Lymphatic Function.

Publications

Development and Clinical Validation of the LymphMonitor Technology to Quantitatively Assess Lymphatic Function.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets